New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 8, 2013
11:10 EDTCZR, BYD, AVNR, ATVI, FSLHigh option volume stocks; FSL AVNR CZR ATVI BYD
News For FSL;AVNR;CZR;ATVI;BYD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 27, 2015
07:01 EDTFSLNXP Semiconductors receives Chinese approval for Freescale merger
Subscribe for More Information
November 25, 2015
16:32 EDTFSLNXP Semiconductors receives FTC approval for merger with Freescale
Subscribe for More Information
15:24 EDTFSLFTC requires NXP Semiconductors to divest RF power amplifier assets
Subscribe for More Information
November 23, 2015
12:08 EDTATVIOn The Fly: Top stock stories at midday
Stocks on Wall Street were slightly higher at midday but have moved in a very narrow trading range throughout the morning. The market, coming off one of its best weeks of the year, appears to be consolidating its gains amid the increased caution that prevails worldwide, highlighted by the ongoing lockdown of Brussels due to its assessment of a "serious and imminent" terrorist threat. There was little help from the day's economic data, as reports on manufacturing and existing home sales both came in below expectations. ECONOMIC EVENTS: In the U.S., Markit's flash manufacturing PMI for November fell 1.5 points to 52.6, missing expectations for a 54.0 reading. Existing home sales dropped 3.4% to a 5.36M rate in October, lower than the forecast for a 5.4M rate. The Chicago Fed National Activity Index showed a reading of -0.04, versus the expected +0.05 reading. In Europe, Markit's composite services and manufacturing PMI rose to 54.4 in October from a prior reading of 53.9. That reading marks the euro-area's highest level since May 2011. COMPANY NEWS: As telegraphed in recent media reports, Pfizer (PFE) and Allergan (AGN) announced plans to combine, creating the world's largest drugmaker. The companies have entered into a definitive merger agreement under which they will combine in a stock transaction valued at $363.63 per Allergan share, for a total enterprise value of approximately $160B, based on the closing price of Pfizer common stock on November 20. Amid concerns that regulators may try to block the huge deal, or make rule changes that will make it less lucrative, Pfizer shares declined more than 2.5% while Allergan saw a similar percentage slide... Alcoa (AA) jumped more than 5% higher after activist investor Elliott Management revealed a 6.4% stake, saying it seeks to engage in a "constructive dialogue" regarding the company's recently spin-off transaction as well as a number of added opportunities it sees to maximize shareholder value. In other activist investor news, Carl Icahn said in an open letter that his talks with AIG (AIG) CEO Peter Hancock make it "abundantly clear" that he is not willing to take the bold steps that Icahn has pushed for, including the suggestion that the insurer separate into three public companies to shrink below the threshold for systemically important financial institutions. Icahn added that he intends to commence shortly a consent solicitation that will enable shareholders to express their views directly to the board, which may include a proposal to add a new director who would agree in advance to succeed Hancock as CEO if asked by the board to do so. MAJOR MOVERS: Among the noteworthy gainers was Tyson Foods (TSN), which rallied 9% after reporting quarterly results and guiding for fiscal 2016. Also higher was Chipotle (CMG), which rebounded 5% after several analysts opined on the company's outlook after shares pulled back Friday as the company confirmed that six new cases of E. coli linked to its restaurants had been identified in four additional states. In addition, SunEdison was up 9% after the company announced that CFO Brian Wuebbels will take over as the president and CEO at its two "YieldCos." Among the notable losers was GameStop (GME), which fell 7.5% after reporting weaker than expected Q3 results. Electronic Arts (EA) and Activision Blizzard (ATVI), whose games are sold at GameStop, slipped nearly 6% and 0.5%, respectively, after the retailer's report. Also lower was Diebold (DBD), which dropped 8% after it announced that it will acquire Wincor Nixdorf in a cash and stock deal valued at $1.8B. INDEXES: Near midday, the Dow was up 7.52, or 0.04%, to 17,831.33, the Nasdaq was up 14.78, or 0.29%, to 5,119.70, and the S&P 500 was up 4.64, or 0.22%, to 2,093.81.
10:18 EDTATVIGameStop plunges on weaker than expected Q3 earnings
Shares of GameStop (GME) are plunging in morning trading after the company reported downbeat third quarter earnings on lower new software and hardware sales and delays in store openings. The company also provided guidance for the fourth quarter and reiterated its outlook for fiscal year 2015. WHAT'S NEW: Before the market open, GameStop reported Q3 adjusted earnings per share of 54c on revenue of $2.02B, below analysts' consensus estimates of 59c and $2.14B, respectively. GameStop added that global same-store sales for the quarter were down 1.1% year over year, with SSS down 1.7% in the United States and up 0.3% internationally. The company said foreign currency negatively impacted EPS by 2c and sales by about $100M and noted that it recorded $1.6M of one-time charges as a result of non-recurring acquisition-related costs. GameStop said new hardware sales declined 20.4%, while new software sales were down 9.3%; pre-owned sales were up 0.6%, the company said. Commenting on the quarter, Chief Executive Officer Paul Raines said that the company's results fell to the low end of its guidance range -- 53c-60c for EPS on SSS up 1% to up 4% -- due to "lower than expected new software and hardware sales and delays in Technology Brands store openings." The company provided an outlook for the fourth quarter, forecasting EPS of $2.12-$2.32, below analysts' estimates of $2.37, and SSS ranging from down 1% to up 6%. Despite the disappointing Q3 earnings and weak Q4 guidance, GameStop affirmed its FY15 EPS view of $3.66-$3.86 and added that it expects full year same store sales to grow 2%-6%. WHAT'S NOTABLE: Prior to the retailer's Q3 earnings report, Steven Russolillo of the Wall Street Journal's Ahead of the tape said that GameStop was "running out of lives" since it has experienced an increasingly challenging video game retail environment due to a rising number of shoppers buying games digitally. Russolillo noted that GameStop's resale business is still profitable and may pare losses somewhat. In addition, NPD Group reported earlier this month a 3% year over year decline in game software retail sales in the U.S. in October. The loss came even despite the major launch of Microsoft's (MSFT) flagship title "Halo 5: Guardians." STREET RESEARCH: Piper Jaffray analyst Michael J. Olson said that GameStop is "clearly" seeing an impact from increasing digital software sales, but that the firm expects digital expansion to ease during the holiday quarter. Olson added that the video game industry is currently in the "renewed growth phase" and that he expects trends in the sector to be strong heading into 2016. The analyst maintained an Overweight rating and $57 price target on the company's stock. PRICE ACTION: In morning trading, GameStop slipped 13.93% to $33.89. The company will hold its earnings conference call at 11am. OTHERS TO WATCH: Video game makers are also lower this morning. Shares of Electronic Arts (EA) are down 2.26%, Take Two Interactive (TTWO) is down 0.84% and Activision Blizzard is down 1.55%.
November 17, 2015
07:18 EDTBYDBoyd Gaming management to meet with Deutsche Bank
Subscribe for More Information
November 16, 2015
09:48 EDTATVIActivision Blizzard management to meet with Brean Capital
Subscribe for More Information
08:07 EDTAVNRConcert Pharmaceuticals achieves $2M milestone from Avanir
Concert Pharmaceuticals (CNCE) announced that it has achieved a $2M milestone under its development and license agreement with Avanir Pharmaceuticals (AVNR) for the progression of the clinical development of AVP-786. The milestone is a result of Avanir initiating dosing of patients in a Phase 3 clinical trial with AVP-786 for the treatment of agitation in patients with Alzheimer's disease. The collaboration agreement between Concert and Avanir provides Avanir with worldwide rights to develop and commercialize AVP-786 and other deuterium-modified dextromethorphan (d-DM) compounds. Under the agreement, Concert is eligible to receive additional milestone payments based upon achievement of certain predefined regulatory and commercial targets. Avanir will continue to have overall responsibility for research, development and commercialization of d-DM compounds, including AVP-786, and Concert is eligible to receive tiered royalties on worldwide sales of any products containing d-DM. The milestone announced today is the third development milestone Concert has earned under this agreement.
08:05 EDTAVNRAvanir initiates Phase III trial of AVP-786
Avanir announced initiation of enrollment into a phase III clinical trial evaluating AVP-786 for the treatment of agitation in patients with Alzheimer's disease. This is the first of two placebo-controlled phase III trials in the company's TRIAD program. Avanir Pharmaceuticals recently received Fast Track designation from the FDA for the development of AVP-786 for this indication. The phase III studies are multicenter, randomized, double-blind, placebo-controlled trials that will evaluate two doses of AVP-786 versus placebo over a period of 12-weeks. Endpoints in these studies will include the Cohen Mansfield Agitation Inventory, the agitation/aggression domain of the Neuropsychiatry Inventory (NPI), other domains of the NPI, measures of global clinical change, and measures of caregiver burden and quality of life. Standard safety measurements will also be performed. TRIAD-1 is expected to enroll approximately 380 patients in 60 centers in the United States. TRIAD-2 is expected to enroll approximately 325 patients in 50 centers in the U.S. and will begin later in 2015. In addition to these two U.S. based trials, there will be additional global trials that will be conducted as part of the TRIAD program. Avanir has also initiated a phase II study to assess the efficacy, safety and tolerability of AVP-786 for the treatment of symptoms associated with residual schizophrenia. This study is expected to enroll approximately 120 patients in the U.S. Additionally, Avanir is currently enrolling patients in a phase II study of AVP-786 for the adjunctive treatment of major depressive disorder. This study began in 2014 and is expected to complete enrollment in 2015.
07:18 EDTBYDDeutsche Bank to hold a conference
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use